Tag: Conference

ATTRibute-CM: Acoramidis Linked to Improved clinical outcomes in transthyretin amyloid cardiomyopathy

Key Points: Transthyretin amyloid cardiomyopathy develops because of mis-folded proteins infiltrating the…

Leah Kosyakovsky

FIRE: Complete revascularization better than culprit-only strategy for elderly with MI and MVD

Key Points The FIRE trial aimed to address the lack of evidence…

Leah Kosyakovsky

Meta-analysis demonstrates that IV Iron is associated with reduced HF hospitalizations in HF patients with iron deficiency

Key Points: Iron-deficiency is common in heart failure (HF) and associated with…

Leah Kosyakovsky

ECLS-SHOCK: ECMO does not reduce mortality in acute MI-related cardiogenic shock compared to control

Key Points: The use of ECLS has increased substantially over the past…

Leah Kosyakovsky

STEP-HFpEF: Semaglutide reduces heart failure symptoms and body weight in HFpEF patients at one year

Key Points: More than 80% of patients with HFpEF are overweight or…

Leah Kosyakovsky

HOST-IDEA: 3-Month DAPT Noninferior to 12-Month DAPT in Patients Undergoing PCI using third-generation stents

Key Points: Among patients undergoing PCI using third-generation DES with ultrathin struts…

Leah Kosyakovsky

UK Biobank Analysis: Self-reported LCHF Diet May be Linked to Cardiac Events

Key Points: In spite of the increase popularity of low-carbohydrate high-fat diet…

Leah Kosyakovsky

hsCRP is a Stronger Predictor of CV Events and Death than LDL-C in High-Risk Patients on Statins

Key Points: Both inflammatory risk and hyperlipidemia and crucial risk factors for…

Leah Kosyakovsky

FREEDOM COVID: Therapeutic dose anticoagulation does not reduce MACE in non-critically ill COVID-19 patients

Key Points: There have been conflicting data on the role and recommended…

Leah Kosyakovsky

STELLAR: Sotatercept improves 6MWD in PAH patients and WHO FC II-III

Key Points: Sotatercept is a novel activin signaling inhibitor which was designed…

Leah Kosyakovsky

Dapagliflozin Reduces PCWP at Rest and Exercise, Plasma Volume, and Weight in HFpEF patients

Key Points: SGLT2i therapy reduces HF hospitalizations and CV mortality in HFpEF,…

Leah Kosyakovsky